Experts at The Institute of Cancer Research, London, have hailed findings from a major international trial showing that a personalised cancer vaccine can significantly reduce the risk of melanoma ...

Nearly one third (29.2 per cent) of patients with advanced melanoma saw their tumours disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, ...

Advocacy engagement: policy and public affairs Our policy priorities Creating a sustainable funding model for research in universities Encouraging international talent to support cancer research ...

Our researchers play key roles in international research efforts that are transforming how these devastating diseases are treated, as well as pioneering studies of cancer types not studied elsewhere ...

A new AI test can pick out which men with high-risk prostate cancer that has not spread will require life-extending drug abiraterone. Scientists from The Institute of Cancer Research, London, and ...

The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Results released at the ...

A targeted cancer treatment given via a simple injection under the skin shrank tumours in more than one third of patients with recurrent and/or metastatic head and neck cancer whose disease has ...

Findings from researchers at The Institute of Cancer Research, London, will help clinicians advise parents of twin children with acute lymphoblastic leukaemia (ALL), offering guidance on risk level ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend that the targeted drug olaparib can be used for locally advanced or metastatic breast cancer. The ...

Radiotheranostics is an exciting new field that has the potential to transform how cancers are detected and treated. Robbie Lockyer finds out more. Radiotheranostics, a groundbreaking approach that ...

The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for a rare form of ovarian cancer by the US regulatory body the Food and Drug Administration (FDA) ...

A new drug is having a dramatic effect on shrinking lung cancer tumours, according to new research. A trial testing the drug zongertinib as a first treatment for people with advanced lung cancer who ...